Pharmacologic Agents to Prevent and Treat Relapse After Allogeneic Hematopoietic Cell Transplantation

Overview

Journal Hematology Am Soc Hematol Educ Program

Specialty Hematology

Date 2017 Dec 10

PMID 29222324

Citations 2

Authors

Robert J Soiffer

Yi-Bin Chen

Affiliations

Soon will be listed here.

Citing Articles

HLA Haplotypes and Relapse After Hematopoietic Cell Transplantation.

Petersdorf E, McKallor C, Malkki M, He M, Spellman S, Gooley T J Clin Oncol. 2023; 42(8):886-897.

PMID: 38051980 PMC: 10927336. DOI: 10.1200/JCO.23.01264.

Immunology of cord blood T-cells favors augmented disease response during clinical pediatric stem cell transplantation for acute leukemia.

Borrill R, Poulton K, Wynn R Front Pediatr. 2023; 11:1232281.

PMID: 37780051 PMC: 10534014. DOI: 10.3389/fped.2023.1232281.

References

Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A . Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2011; 26(3):381-9. PMC: 3306138. DOI: 10.1038/leu.2011.234. View

Lindsley R, Saber W, Mar B, Redd R, Wang T, Haagenson M . Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017; 376(6):536-547. PMC: 5438571. DOI: 10.1056/NEJMoa1611604. View

Brissot E, Labopin M, Beckers M, Socie G, Rambaldi A, Volin L . Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2014; 100(3):392-9. PMC: 4349279. DOI: 10.3324/haematol.2014.116954. View

Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A . Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. Cancer. 2017; 123(15):2867-2874. DOI: 10.1002/cncr.30680. View

Goodyear O, Dennis M, Jilani N, Loke J, Siddique S, Ryan G . Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012; 119(14):3361-9. DOI: 10.1182/blood-2011-09-377044. View

Alsina M, Becker P, Zhong X, Adams A, Hari P, Rowley S . Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014; 20(8):1183-9. PMC: 5036168. DOI: 10.1016/j.bbmt.2014.04.014. View

Bjorkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F . Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and.... Bone Marrow Transplant. 2001; 27(5):511-5. DOI: 10.1038/sj.bmt.1702826. View

Ryan C, Sahaf B, Logan A, OBrien S, Byrd J, Hillmen P . Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016; 128(25):2899-2908. PMC: 5179333. DOI: 10.1182/blood-2016-06-715284. View

Sockel K, Bornhaeuser M, Mischak-Weissinger E, Trenschel R, Wermke M, Unzicker C . Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial. Haematologica. 2012; 97(9):e34-5. PMC: 3436225. DOI: 10.3324/haematol.2012.067629. View

10.

Teng C, Yu J, Chen H, Hwang W . Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Hematol. 2013; 92(8):1137-9. DOI: 10.1007/s00277-012-1670-4. View

11.

Pagel J, Gooley T, Rajendran J, Fisher D, Wilson W, Sandmaier B . Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood. 2009; 114(27):5444-53. PMC: 2798861. DOI: 10.1182/blood-2009-03-213298. View

12.

DeFilipp Z, Chen Y . Strategies and Challenges for Pharmacological Maintenance Therapies after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016; 22(12):2134-2140. DOI: 10.1016/j.bbmt.2016.08.021. View

13.

Clift R, Buckner C, Appelbaum F, Bearman S, Petersen F, Fisher L . Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990; 76(9):1867-71. View

14.

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T . Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19):1782-91. DOI: 10.1056/NEJMoa1114138. View

15.

de Lima M, Giralt S, Thall P, de Padua Silva L, Jones R, Komanduri K . Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010; 116(23):5420-31. PMC: 5669059. DOI: 10.1002/cncr.25500. View

16.

Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton W, Metzner B . Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013; 31(13):1624-30. DOI: 10.1200/JCO.2012.47.1862. View

17.

Sivaraj D, Green M, Li Z, Sung A, Sarantopoulos S, Kang Y . Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant. 2016; 23(2):262-268. PMC: 11099879. DOI: 10.1016/j.bbmt.2016.11.010. View

18.

Wingard J, Majhail N, Brazauskas R, Wang Z, Sobocinski K, Jacobsohn D . Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011; 29(16):2230-9. PMC: 3107742. DOI: 10.1200/JCO.2010.33.7212. View

19.

Thanarajasingam G, Kim H, Cutler C, Ho V, Koreth J, Alyea E . Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 19(12):1713-8. PMC: 3848699. DOI: 10.1016/j.bbmt.2013.09.011. View

20.

Shimoni A, Hardan I, Shem-Tov N, Yerushalmi R, Nagler A . Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up. Leukemia. 2010; 24(5):1050-2. DOI: 10.1038/leu.2010.12. View